ORIENT-15
Regimen
- Experimental
- sintilimab + cisplatin/paclitaxel (or cisplatin/5-FU)
- Control
- placebo + cisplatin/paclitaxel (or cisplatin/5-FU)
Population
Systemic-therapy-naive locally advanced or metastatic ESCC
Key finding
All pts mOS 16.7 vs 12.5 mo (HR 0.63, 95% CI 0.51-0.78, p<0.001); CPS>=10 mOS 17.2 vs 13.6 mo (HR 0.64, p=0.002); PFS 7.2 vs 5.7 mo (HR 0.56)
Source: PMID 35440464